keyword
MENU ▼
Read by QxMD icon Read
search

Stage IV lung cancer

keyword
https://www.readbyqxmd.com/read/28230011/changes-of-cd4-t-cell-subsets-after-radiofrequency-ablation-in-lung-cancer-and-its-significance
#1
Wang Shaobin, Xiong Yu, Lin Jiatian, Chen Zaizhong, Dai Luping, Chen Junhui
AIMS: To analyze the changes of CD4+ T-cell subsets following radiofrequency ablation (RFA) in lung cancer and the impact of RFA on the antitumor immunity. SUBJECTS AND METHODS: Flow cytometry was employed to detect CD4+ T-cell subsets in the peripheral blood from 45 healthy controls and 45 lung cancer patients before and after RFA. The correlation between CD4+ T-cell subsets and the clinical characteristics was discussed by comparing the results between different groups...
December 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28218046/thyroid-transcription-factor-1-expression-is-associated-with-outcome-of-patients-with-non-squamous-non-small-cell-lung-cancer-treated-with-pemetrexed-based-chemotherapy
#2
Ondrej Fiala, Milos Pesek, Jana Skrickova, Vitezslav Kolek, Frantisek Salajka, Marcela Tomiskova, Monika Satankova, Juraj Kultan, Jana Kuliskova, Martin Svaton, Michal Hrnciarik, Karel Hejduk, Renata Chloupkova, Ondrej Topolcan, Helena Hornychova, Marketa Nova, Ales Ryska, Jindrich Finek
Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed...
February 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28213005/is-clarithromycin-a-potential-treatment-for-cachexia-in-people-with-lung-cancer-a-feasibility-study
#3
Sarah Awan, Vincent Crosby, Vanessa Potter, Ivo Hennig, David Baldwin, Mehluli Ndlovu, Sharon Paradine, Andrew Wilcock
Clarithromycin may improve cachexia and survival in non-small cell lung cancer (NSCLC), but adequately controlled data are lacking. This study was undertaken primarily to inform the feasibility and scale of a phase III trial. Eligible consenting patients with stage IV NSCLC and cachexia were to be randomized to receive either clarithromycin 250mg twice daily or placebo for eight weeks. Aspects of trial feasibility recorded included numbers eligible, approached and recruited, together with adherence and completion of treatment and assessments...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28212993/efficacy-according-to-blind-independent-central-review-post-hoc-analyses-from-the-phase-iii-randomized-multicenter-ipass-study-of-first-line-gefitinib-versus-carboplatin-paclitaxel-in-asian-patients-with-egfr-mutation-positive-advanced-nsclc
#4
Yi-Long Wu, Nagahiro Saijo, Sumitra Thongprasert, J C-H Yang, Baohui Han, Benjamin Margono, Busayamas Chewaskulyong, Patrapim Sunpaweravong, Yuichiro Ohe, Yukito Ichinose, Jin-Ji Yang, Tony S K Mok, Helen Young, Vincent Haddad, Yuri Rukazenkov, Masahiro Fukuoka
OBJECTIVE: The Phase III, randomized, open-label IPASS study (NCT00322452) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib versus carboplatin/paclitaxel for Asian patients with advanced non-small-cell lung cancer (NSCLC) showed that investigator-assessed progression-free survival (PFS) and objective response rate (ORR) were significantly prolonged in patients with EGFR mutation-positive NSCLC who received gefitinib versus patients with EGFR mutation-negative NSCLC...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28212540/expression-of-met-in-circulating-tumor-cells-correlates-with-expression-in-tumor-tissue-from-advanced-stage-lung-cancer-patients
#5
Marius Ilie, Edith Szafer-Glusman, Véronique Hofman, Elodie Long-Mira, Rebecca Suttmann, Walter Darbonne, Catherine Butori, Salomé Lalvée, Julien Fayada, Eric Selva, Wei Yu, Charles-Hugo Marquette, David S Shames, Elizabeth Punnoose, Paul Hofman
Given the difficulty in obtaining adequate tissue in NSCLC, we investigated the utility of circulating tumor cells (CTCs) for MET status assessment in NSCLC patients. We used two platforms for CTC capture, and assessed MET expression in CTCs and matched-bronchial biopsies in patients with advanced-stage III/IV lung adenocarcinoma. Baseline peripheral blood was collected from 256 advanced-stage III/IV NSCLC patients from Genentech clinical trials, and from 106 patients with advanced-stage III/IV lung adenocarcinoma treated at the Department of Pneumology, Pasteur Hospital, Nice...
February 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28209123/relationships-between-longitudinal-neutrophil-to-lymphocyte-ratios-body-weight-changes-and-overall-survival-in-patients-with-non-small-cell-lung-cancer
#6
B A Derman, J N Macklis, M S Azeem, S Sayidine, S Basu, M Batus, F Esmail, J A Borgia, P Bonomi, M J Fidler
BACKGROUND: There is emerging evidence showing a significant relationship between overall survival (OS) in non-small cell lung cancer NSCLC patients and weight change during chemotherapy or chemoradiation. A high neutrophil/lymphocyte ratio (NLR) at baseline and at follow-up is associated with shorter survival in cancer patients and may be a surrogate for ongoing inflammation, implicated in cancer cachexia and tumor progression. The objective of this study is to explore potential relationships between OS, serial weights, and serial NLRs in advanced NSCLC patients receiving chemotherapy...
February 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28204910/outcomes-of-curative-intent-surgery-and-adjuvant-treatment-for-pulmonary-large-cell-neuroendocrine-carcinoma
#7
Kun Woo Kim, Hong Kwan Kim, Jhingook Kim, Young Mog Shim, Myung-Ju Ahn, Yoon-La Choi
BACKGROUND: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is pathologically classified as non-small-cell lung cancer (NSCLC), but its clinical behavior is more aggressive than other types of NSCLC. Accordingly, the optimal treatment strategy for LCNEC, including the indication of adjuvant treatment, remains controversial. METHODS: A retrospective review of 139 patients who underwent curative-intent surgery for LCNEC was performed to investigate clinicopathologic features and survival outcomes and to evaluate whether adjuvant treatment affected survival outcomes...
February 15, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28203414/advanced-primary-pulmonary-lymphoepithelioma-like-carcinoma-clinical-manifestations-treatment-and-outcome
#8
Chun-Yu Lin, Ying-Jen Chen, Meng-Heng Hsieh, Chih-Wei Wang, Yueh-Fu Fang
BACKGROUND: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is rare, with better clinical outcomes than other lung cancers. However, reports on advanced LELC characteristics and prognosis are lacking. METHODS: This retrospective study included adults diagnosed with advanced LELC (at least stage IIIA) between January 2003 and December 2015. Clinical characteristics, treatment modalities, and outcomes were recorded. RESULTS: Study population comprised 23 patients with a mean age of 63...
January 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28203086/clinical-investigation-into-the-initial-diagnosis-and-treatment-of-539-patients-with-stage-iv-lung-cancer
#9
Qian Shao, Shanshan Liu, Wei Wang, Yingjie Zhang, Fengxiang Li, Jianbin Li
OBJECTIVE: The aim of the study was to analyze clinical data, including the types of pathologic classification, metastatic organs, treatment strategy, and prognosis of patients with stage IV lung cancer. METHODS: A retrospective analysis of the clinical features of 539 patients with stage IV lung cancer who were initially diagnosed and treated in 2009 was conducted. There were 146 cases of single organ metastases and 393 cases of multiple organ metastases. The Kaplan-Meier method and multivariate Cox regression analysis were performed to analyze the influence of age, pathological classification, metastatic organs, and treatment strategy on overall survival...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28202905/risk-factors-for-brain-metastases-after-prophylactic-cranial-irradiation-in-small-cell-lung-cancer
#10
Haiyan Zeng, Peng Xie, Xue Meng, Shuanghu Yuan, Xindong Sun, Wanlong Li, Bingjie Fan, Xiaolin Li, Jinming Yu
Despite administration of prophylactic cranial irradiation (PCI), some small cell lung cancer (SCLC) patients still suffer from brain metastases (BM) with unknown risk factors. We conducted this study to identify patients with higher BM risk after PCI and improve their outcome. The characteristics and survival of all the SCLC patients underwent PCI in our institute from 2003 to 2014 were analyzed. Kaplan-Meier method was applied to estimate BM free survival (BMFS) and overall survival (OS). Cox regression analyses were performed to explore risk factors for BM...
February 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28202209/characteristics-and-prognosis-of-japanese-male-and-female-lung-cancer-patients-the-biobank-japan-project
#11
Koshi Nakamura, Shigekazu Ukawa, Emiko Okada, Makoto Hirata, Akiko Nagai, Zentaro Yamagata, Toshiharu Ninomiya, Kaori Muto, Yutaka Kiyohara, Koichi Matsuda, Yoichiro Kamatani, Michiaki Kubo, Yusuke Nakamura, Akiko Tamakoshi
BACKGROUND: In Japanese males and females, lung cancer is currently the second and fourth most common type of cancer, and the first and second leading cause of cancer-related deaths, respectively. METHODS: Of all Japanese male and female lung cancer patients aged ≥20 years whom the BioBank Japan Project originally enrolled between 2003 and 2008, 764 males and 415 females were registered within 90 days after their diagnosis. We described the lifestyle and clinical characteristics of these patients at study entry...
February 13, 2017: Journal of Epidemiology
https://www.readbyqxmd.com/read/28197929/epithelial-mesenchymal-transition-emt-and-non-small-cell-lung-cancer-nsclc-a-mutual-association-with-airway-disease
#12
Malik Quasir Mahmood, Chris Ward, Hans Konrad Muller, Sukhwinder Singh Sohal, Eugene Haydn Walters
NSCLC is a leading cause of morbidity and mortality worldwide. It includes adeno- and squamous cell carcinoma. In the background, COPD and smoking play a vital role in development of NSCLC. Local progression and metastasis of NSCLC has been associated with various mechanisms, but in particular by a process called epithelial mesenchymal transition (EMT), which is implicated in COPD pathogenesis. In this study, we have investigated whether expression of EGFR (activation marker) and S100A4, vimentin and N-cadherin (as EMT) is different both in central and leading edge of NSCLC and to what extent related to EMT activity of both small and large airways, stage and differentiation of NSCLC...
March 2017: Medical Oncology
https://www.readbyqxmd.com/read/28190599/retrospective-analysis-of-different-treatment-schemes-after-gefitinib-resistance-in-advanced-non-small-cell-lung-cancer
#13
Huijuan Wang, Mina Zhang, Peng Li, Guowei Zhang, Xiangtao Yan, Zhiyong Ma
PURPOSE: The goal of this study was to assess the survival of patients with acquired resistance to gefitinib who underwent different subsequent treatments. METHODS: From September 2007 to July 2014, a total of 103 patients with pathologically confirmed advanced non-small cell lung cancer and acquired resistance to gefitinib were retrospectively analyzed. Fifty-eight (56%) patients received chemotherapy; 36 were treated with chemotherapy and gefitinib continuation (CT + G), and 22 patients received chemotherapy (CT) alone...
February 9, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28185464/differences-in-age-distribution-oncological-diagnoses-and-stage-in-roma-and-non-roma-cancer-patients-registered-at-the-outpatient-oncology-department-poprad-in-2014-and-2015-a-retrospective-study
#14
M Reckova, J Mardiak, J Beniak, M Kakalejcik, L Medvecova, S Cingelová, M Mego
BACKGROUND: Roma (Gypsies) constitute the largest ethnic minority in Slovakia. Although some studies have reported a higher prevalence of communicable diseases in Roma, there have been no studies on cancer prevalence in Roma. The aim of this study was to compare differences in age at diagnosis, oncological diagnoses, and stage between Roma and non-Roma patients registered at a single oncology outpatient department in Eastern Slovakia where substantial numbers of Roma patients are treated...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28183714/dichotomous-alk-ihc-is-a-better-predictor-for-alk-inhibition-outcome-than-traditional-alk-fish-in-advanced-non-small-cell-lung-cancer
#15
Anthonie van der Wekken, Rianne Pelgrim, Nils 't Hart, Naomi Werner, Mirjam Mastik, Lizza Hendriks, Erik Hfm van der Heijden, Monika Looijen-Salamon, A Joop de Langen, Jeske Staal-van den Brekel, Sietske Riemersma, Ben E van den Borne, Ernst-Jan M Speel, Anne-Marie C Dingemans, T Jeroen N Hiltermann, Anke van den Berg, Wim Timens, Ed Schuuring, Harry Jm Groen
ALK rearrangement detection using fluorescence in situ hybridization (FISH) is the standard test to identify non-small cell lung carcinoma (NSCLC) patients eligible for treatment with ALK inhibitors. Recently ALK protein expression in resectable NSCLC showed predictive value. We evaluated tumor response rate and survival after crizotinib treatment of advanced NSCLC patients with ALK activation using both dichotomous immunohistochemical staining (IHC) and FISH. Design Stage IV NSCLC patients treated with crizotinib were selected...
February 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28181415/a-phase-ii-trial-of-concurrent-chemotherapy-with-intravenous-cisplatin-and-vinorelbine-and-radiotherapy-followed-by-consolidation-chemotherapy-with-oral-vinorelbine-in-locally-advanced-non-small-cell-lung-cancer-nsclc-the-concave-study
#16
Brett Gm Hughes, Elizabeth Ahern, Margot Lehman, Gary Pratt, Margaret Dauth, Wendy Pritchard, Leesa Wockner, Keith Horwood
AIM: Despite recent advances, outcomes for patients with stage III non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy (CRT) remain poor. We evaluated the combination of ciplatin/vinorelbine and concurrent thoracic radiotherapy followed by consolidation oral vinorelbine in this phase II study. METHODS: Eligible patients with unresectable stage III NSCLC received cisplatin intravenous (IV) 40 mg/m(2) and vinorelbine IV 20 mg/m(2) on days 1, 8, 22 and 29 concurrent with thoracic radiotherapy of 60 Gy in 30 fractions...
February 9, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28179353/carboplatin-plus-weekly-paclitaxel-combined-with-bevacizumab-as-first-line-treatment-for-non-small-cell-lung-cancer
#17
Masahiro Yamasaki, Isao Murakami, Kikuo Nakano, Mihoko Doi, Souichi Kitaguchi, Tomohiro Kondo, Joji Sakurai, Noboru Hattori, Ken-Ichi Arita
AIM: We aimed to evaluate the efficacy and safety of carboplatin plus weekly paclitaxel with bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with stage IIIB/IV or postoperative recurrent NSCLC (n=33) were treated with carboplatin (area under the curve of 6) on day 1; paclitaxel (80 mg/m(2)) on days 1, 8, and 15; and bevacizumab (15 mg/kg) on day 1 repeated every 4 weeks, for four to six cycles; followed by maintenance bevacizumab (15 mg/kg) every 3 weeks...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28177518/unique-prevalence-of-oncogenic-genetic-alterations-in-young-patients-with-lung-adenocarcinoma
#18
Kosuke Tanaka, Toyoaki Hida, Yuko Oya, Tatsuya Yoshida, Junichi Shimizu, Tetsuya Mizuno, Hiroaki Kuroda, Noriaki Sakakura, Kenichi Yoshimura, Yoshitsugu Horio, Yukinori Sakao, Yasushi Yatabe
BACKGROUND: Lung adenocarcinoma in the young is a rare entity, and the oncogenic genetic alterations (GAs) and clinical characteristics associated with this disease are poorly understood. Conversely, it has been demonstrated that young age at diagnosis defines unique biology in other cancers. For this report, the effects of young age on lung adenocarcinoma are reported. METHODS: The authors retrospectively screened 1746 consecutive patients who were diagnosed with stage I through IV adenocarcinoma between 2009 and 2015 and identified 81 who were aged 40 years or younger at diagnosis...
February 8, 2017: Cancer
https://www.readbyqxmd.com/read/28174383/-a-case-of-synchronous-double-cancer-of-the-lung-and-stomach-that-responded-to-cisplatin-and-s-1-combination-chemotherapy
#19
Tomohide Sugiyama, Takashi Kasai, Yoichi Nakamura, Yukari Kamiyama, Kiyoshi Mori
A 55-year-old man experienced weight loss, as noted by a physician who was examining him for hypertension. Upper gastrointestinal endoscopy revealed a tumor lesion with an ulcer on the posterior wall of the greater curvature. A biopsy confirmed the presence of an adenocarcinoma(HER2 negative), and demonstrated enlarged para-aortic lymph nodes. Thus, stage IV type 3 ulcer infiltration-type gastric cancer was diagnosed. Computed tomography was included in the examination, and demonstrated nodular shadows in the right lower lobe and enlarged mediastinal nodes, as well as bilateral multiple granular shadows...
January 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28174382/-persistent-chemotherapy-induced-hiccups-successfully-treated-with-pregabalin
#20
Kyoko Nakanishi, Kumi Sugiyama, Yasushi Abe, Tetsushi Endo, Yoshinobu Ohsaki
A 62-year-old male was diagnosed with large cell lung cancer(c-Stage IV)based on pathological examination of an anterior chest tumor. He received chemotherapy with cisplatin, pemetrexed, and bevacizumab. He suffered from persistent hiccups from day 2 of the first course of chemotherapy. He was unsuccessfully treated with chlorpromazine, shakuyakukanzoto, and gabapentin. Therefore, we administered pregabalin to him, and his hiccups subsided immediately. To prevent hiccups, he subsequently took pregabalin along with his chemotherapy regimen, and was able to receive 4 courses of chemotherapy without persistent hiccups...
January 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
41253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"